Caution about ketoacidosis, UTIs, and other serious ADRs with the SGLT2s

More warnings for the SGLT2 inhibitors (canagliflozin, etc) will increase concerns about their safety.

These "flozins" are popular oral diabetes meds because they have a low risk of hypoglycemia...lead to modest weight loss...and can lower BP.

Plus empagliflozin (Jardiance) has CV benefits including a reduced risk of cardiovascular death and heart failure hospitalizations.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals